Supportive Care in Cancer

, Volume 27, Issue 3, pp 1001–1011 | Cite as

Physical activity and associations with treatment-induced adverse effects among prostate cancer patients

  • Synne-Kristin Hoffart BøhnEmail author
  • Sophie Dorothea Fosså
  • Torbjørn Wisløff
  • Lene Thorsen
Original Article



The present study aimed to determine the level of physical activity (PA) among prostate cancer (PCa) patients across treatment modalities and explore the association between PA and treatment-induced adverse effects (AEs).


The present study was based on a cross-sectional postal survey among members of the Norwegian Prostate Cancer Association. Patients were eligible for the present study if they had either (1) completed radical prostatectomy, (2) completed radiotherapy and (neo)-adjuvant androgen deprivation therapy (ADT), or (3) were undergoing lifelong ADT. Adverse effects were measured by the Expanded Prostate Cancer Index Composite for Clinical Practice.


In total, 696 patients were included. There was no statistically significant difference in level of PA across treatment modalities. Bowel symptoms mainly related to radiotherapy decreased the odds of exercising ≥ 2 times per week, along with age ≥ 70 years, participation in the workforce, and BMI ≥ 25 kg/m2. Among patients who were undergoing ADT, 5 years or more since diagnosis reduced the odds of exercising ≥ 2 times per week by almost 60%.


The level of PA did not differ across PCa patients treated with different modalities. Increasing bowel symptoms reduced the likelihood of exercising ≥ 2 times per week. PCa patients should be educated about possible treatment-induced AEs affecting PA level, enabling them to counteract the development of physical inactivity.


Prostate cancer Physical activity Treatment-induced adverse effects Radiotherapy Androgen deprivation therapy Prostatectomy 



This study was funded by the Norwegian Cancer Society (project no. 45980 – Norwegian Consortium on Late Effects after Cancer).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Supplementary material

520_2018_4389_MOESM1_ESM.jpg (58 kb)
Supplementary Figure 1 (JPG 58 kb)
520_2018_4389_MOESM2_ESM.jpg (62 kb)
Supplementary Figure 2 (JPG 61 kb)
520_2018_4389_MOESM3_ESM.jpg (61 kb)
Supplementary Figure 3 (JPG 60 kb)
520_2018_4389_MOESM4_ESM.jpg (56 kb)
Supplementary Figure 4 (JPG 55 kb)
520_2018_4389_MOESM5_ESM.jpg (40 kb)
Supplementary Figure 5 (JPG 39 kb)


  1. 1.
    Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2012) Global Cancer statistics. CA Cancer J Clin 2015:87–108Google Scholar
  2. 2.
    Cancer Registry of Norway (2017) Cancer in Norway 2016 - Cancer incidence, mortality, survival and prevalence in Norway. Cancer Registry of Norway, OsloGoogle Scholar
  3. 3.
    Solberg A, Angelsen A, Berge V (2013) Nasjonalt handlings program med retningslinjer for diagnostikk, behandling og oppfølging av prostatakreft. Oslo, HelsedirektoratetGoogle Scholar
  4. 4.
    Carlsson S, Drevin L, Loeb S, Widmark A, Lissbrant IF, Robinson D, Johansson E, Stattin P, Fransson P (2016) Population-based study of long-term functional outcomes after prostate cancer treatment. BJU Int 117(6B):E36–E45Google Scholar
  5. 5.
    Stanford JL, Feng Z, Hamilton AS, Gilliland FD, Stephenson RA, Eley JW, Albertsen PC, Harlan LC, Potosky AL (2000) Urinary and sexual function after radical prostatectomy for clinically localized prostate cancer: the prostate cancer outcomes study. JAMA 283(3):354–360Google Scholar
  6. 6.
    Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, Lin X, Greenfield TK, Litwin MS, Saigal CS, Mahadevan A, Klein E, Kibel A, Pisters LL, Kuban D, Kaplan I, Wood D, Ciezki J, Shah N, Wei JT (2008) Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 358(12):1250–1261Google Scholar
  7. 7.
    Galvao DA, Taaffe DR, Spry N, Joseph D, Turner D, Newton RU (2009) Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigation. Prostate Cancer Prostatic Dis 12(2):198–203Google Scholar
  8. 8.
    Storey DJ, McLaren DB, Atkinson MA, Butcher I, Frew LC, Smyth JF, Sharpe M (2012) Clinically relevant fatigue in men with hormone-sensitive prostate cancer on long-term androgen deprivation therapy. Ann Oncol 23(6):1542–1549Google Scholar
  9. 9.
    Nguyen PL, Alibhai SMH, Basaria S, D’Amico AV, Kantoff PW, Keating NL, Penson DF, Rosario DJ, Tombal B, Smith MR (2015) Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol 67(5):825–836Google Scholar
  10. 10.
    Keating NL, O'Malley AJ, Smith MR (2006) Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 24(27):4448–4456Google Scholar
  11. 11.
    Speck RM, Courneya KS, Masse LC, Duval S, Schmitz KH (2010) An update of controlled physical activity trials in cancer survivors: a systematic review and meta-analysis. J Cancer Surviv 4(2):87–100Google Scholar
  12. 12.
    Schmitz KH, Courneya KS, Matthews C, Demark-Wahnefried W, Galvao DA, Pinto BM, Irwin ML, Wolin KY, Segal RJ, Lucia A et al (2010) American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc 42(7):1409–1426Google Scholar
  13. 13.
    Gardner JR, Livingston PM, Fraser SF (2014) Effects of exercise on treatment-related adverse effects for patients with prostate cancer receiving androgen-deprivation therapy: a systematic review. J Clin Oncol 32(4):335–346Google Scholar
  14. 14.
    Galvao DA, Newton RU, Gardiner RA, Girgis A, Lepore SJ, Stiller A et al (2015) Compliance to exercise-oncology guidelines in prostate cancer survivors and associations with psychological distress, unmet supportive care needs, and quality of life. Psycho-oncology 24(10):1241–9 Google Scholar
  15. 15.
    Gjerset GM, Fossa SD, Courneya KS, Skovlund E, Thorsen L (2011) Exercise behavior in cancer survivors and associated factors. J Cancer Surviv 5(1):35–43Google Scholar
  16. 16.
    Thorsen L, Courneya KS, Stevinson C, Fosså SD (2008) A systematic review of physical activity in prostate cancer survivors: outcomes, prevalence, and determinants. Support Care Cancer 16(9):987–997Google Scholar
  17. 17.
    Blanchard CM, Courneya KS, Stein K (2008) Cancer survivors’ adherence to lifestyle behavior recommendations and associations with health-related quality of life: results from the American Cancer Society’s SCS-II. J Clin Oncol 26(13):2198–2204Google Scholar
  18. 18.
    Forbes CC, Blanchard CM, Mummery WK, Courneya KS (2014) A comparison of physical activity correlates across breast, prostate and colorectal cancer survivors in Nova Scotia, Canada. Support Care Cancer 22(4):891–903Google Scholar
  19. 19.
    Chipperfield K, Fletcher J, Millar J, Brooker J, Smith R, Frydenberg M, Oh T, Burney S (2013) Factors associated with adherence to physical activity guidelines in patients with prostate cancer. Psycho-Oncology 22(11):2478–2486Google Scholar
  20. 20.
    Henriksson A, Arving C, Johansson B, Igelström H, Nordin K (2016) Perceived barriers to and facilitators of being physically active during adjuvant cancer treatment. Patient Educ Couns 99(7):1220–1226Google Scholar
  21. 21.
    Craike MJ, Livingston PM, Botti M (2011) An exploratory study of the factors that influence physical activity for prostate cancer survivors. Support Care Cancer 19(7):1019–1028Google Scholar
  22. 22.
    Geraerts I, Van Poppel H, Devoogdt N, Laenen A, De Groef A, Van Kampen M (2014) Progression and predictors of physical activity levels after radical prostatectomy. BJU Int 114(2):185–192Google Scholar
  23. 23.
    Ottenbacher A, Sloane R, Snyder DC, Kraus W, Sprod L, Demark-Wahnefried W (2013) Cancer-specific concerns and physical activity among recently diagnosed breast and prostate cancer survivors. Integr Cancer Ther 12(3):206–212Google Scholar
  24. 24.
    Fossa SD, Dahl AA (2015) Global quality of life after curative treatment for prostate cancer: what matters? A study among members of the Norwegian prostate cancer patient association. Clin Genitourin Cancer 13(6):518–24 Google Scholar
  25. 25.
    Kurtze N, Rangul V, Hustvedt BE, Flanders WD (2008) Reliability and validity of self-reported physical activity in the Nord-Trondelag Health Study: HUNT 1. Scand J Public Health 36(1):52–61Google Scholar
  26. 26.
    Chang P, Szymanski KM, Dunn RL, Chipman JJ, Litwin MS, Nguyen PL, Sweeney CJ, Cook R, Wagner AA, DeWolf WC et al (2011) Expanded prostate cancer index composite for clinical practice: development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancer. J Urol 186(3):865–872Google Scholar
  27. 27.
    Szymanski KM, Wei JT, Dunn RL, Sanda MG (2010) Development and validation of an abbreviated version of the expanded prostate cancer index composite instrument for measuring health-related quality of life among prostate cancer survivors. Urology 76(5):1245–50 Google Scholar
  28. 28.
    Chipman JJ, Sanda MG, Dunn RL, Wei JT, Litwin MS, Crociani CM et al (2014) Measuring and predicting prostate cancer related quality of life changes using EPIC for clinical practice. J Urol 191(3):638–45Google Scholar
  29. 29.
    Tsumura H, Satoh T, Ishiyama H, Hirano S, Tabata K, Kurosaka S, Matsumoto K, Fujita T, Kitano M, Baba S, Hayakawa K, Iwamura M (2015) Recovery of serum testosterone following neoadjuvant and adjuvant androgen deprivation therapy in men treated with prostate brachytherapy. World J Radiol 7(12):494–500Google Scholar
  30. 30.
    Fisher A, Wardle J, Beeken RJ, Croker H, Williams K, Grimmett C (2016) Perceived barriers and benefits to physical activity in colorectal cancer patients. Support Care Cancer 24:903–910Google Scholar
  31. 31.
    Blaney JM, Lowe-Strong A, Rankin-Watt J, Campbell A, Gracey JH (2013) Cancer survivors’ exercise barriers, facilitators and preferences in the context of fatigue, quality of life and physical activity participation: a questionnaire–survey. Psycho-Oncology 22(1):186–194Google Scholar
  32. 32.
    Hansen BH, Kolle E, Anderssen SA (2014) Fysisk aktivitetsnivå blant voksne og eldre i Norge Oppdaterte analyser basert på nye nasjonale anbefalinger i 2014. Oslo, HelsedirektoratetGoogle Scholar
  33. 33.
    Keogh JW, Patel A, MacLeod RD, Masters J (2014) Perceived barriers and facilitators to physical activity in men with prostate cancer: possible influence of androgen deprivation therapy. Eur J Cancer Care (Engl) 23(2):263–273Google Scholar
  34. 34.
    Smith MR, Saad F, Egerdie B, Sieber PR, Tammela TL, Ke C, Leder BZ, Goessl C (2012) Sarcopenia during androgen-deprivation therapy for prostate cancer. J Clin Oncol 30(26):3271–3276Google Scholar
  35. 35.
    Nelson AM, Gonzalez BD, Jim HS, Cessna JM, Sutton SK, Small BJ, Fishman MN, Zachariah B, Jacobsen PB (2016) Characteristics and predictors of fatigue among men receiving androgen deprivation therapy for prostate cancer: a controlled comparison. Support Care Cancer 24(10):4159–4166Google Scholar
  36. 36.
    Sallis JF (2000) Age-related decline in physical activity: a synthesis of human and animal studies. Med Sci Sports Exerc 32(9):1598–1600Google Scholar
  37. 37.
    Morseth B, Jacobsen BK, Emaus N, Wilsgaard T, Jorgensen L (2016) Secular trends and correlates of physical activity: the Tromso Study 1979-2008. BMC Public Health 16(1):1215Google Scholar
  38. 38.
    Ottenbacher AJ, Day RS, Taylor WC, Sharma SV, Sloane R, Snyder DC, Kraus WE, Demark-Wahnefried W (2011) Exercise among breast and prostate cancer survivors--what are their barriers? J Cancer Surviv 5(4):413–419Google Scholar
  39. 39.
    Olanrewaju O, Kelly S, Cowan A, Brayne C, Lafortune L (2016) Physical activity in community dwelling older people: a systematic review of reviews of interventions and context. PLoS One 11(12):e0168614Google Scholar
  40. 40.
    Forbes CC, Blanchard CM, Mummery WK, Courneya K (2015) Prevalence and correlates of strength exercise among breast, prostate, and colorectal cancer survivors. Oncol Nurs Forum 42(2):118–127Google Scholar
  41. 41.
    Kampshoff CS, Stacey F, Short CE, van Mechelen W, Chinapaw MJM, Brug J, Plotnikoff R, James EL, Buffart LM (2016) Demographic, clinical, psychosocial, and environmental correlates of objectively assessed physical activity among breast cancer survivors. Support Care Cancer 24:3333–3342Google Scholar
  42. 42.
    Troiano RP (2007) Large-scale applications of accelerometers: new frontiers and new questions. Med Sci Sports Exerc 39(9):1501Google Scholar
  43. 43.
    Schechtman KB, Barzilai B, Rost K, Fisher EB Jr (1991) Measuring physical activity with a single question. Am J Public Health 81(6):771–773Google Scholar
  44. 44.
    Demarest S, Van Oyen H, Roskam AJ, Cox B, Regidor E, Mackenbach JP, Kunst AE (2014) Educational inequalities in leisure-time physical activity in 15 European countries. Eur J Pub Health 24(2):199–204Google Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.National Advisory Unit on Late Effects after Cancer Treatment, Department of OncologyOslo University Hospital OsloNorway
  2. 2.Faculty of MedicineUniversity of OsloOsloNorway
  3. 3.Department of Infectious Disease Epidemiology and Modelling, Norwegian Institute of Public Health, and Department of Health Management and Health EconomicsUniversity of OsloOsloNorway
  4. 4.Department of Clinical ServiceOslo University HospitalOsloNorway

Personalised recommendations